Abstract:As a chronic metabolic disease, diabetes mellitus (DM) is broadly characterized by elevated levels of blood glucose. Novel epidemiological studies demonstrate that some diabetic patients have an increased risk of developing dementia compared with healthy individuals. Alzheimer’s disease (AD) is the most frequent cause of dementia and leads to major progressive deficits in memory and cognitive function. Multiple studies have identified an increased risk for AD in some diabetic populations, but it is still unclear which diabetic patients will develop dementia and which biological characteristics can predict cognitive decline. Although few mechanistic metabolic studies have shown clear pathophysiological links between DM and AD, there are several plausible ways this may occur. Since AD has many characteristics in common with impaired insulin signaling pathways, AD can be regarded as a metabolic disease. We conclude from the published literature that the body’s diabetic status under certain circumstances such as metabolic abnormalities can increase the incidence of AD by affecting glucose transport to the brain and reducing glucose metabolism. Furthermore, due to its plentiful lipid content and high energy requirement, the brain’s metabolism places great demands on mitochondria. Thus, the brain may be more susceptible to oxidative damage than the rest of the body. Emerging evidence suggests that both oxidative stress and mitochondrial dysfunction are related to amyloid- β (A β ) pathology. Protein changes in the unfolded protein response or endoplasmic reticulum stress can regulate A β production and are closely associated with tau protein pathology. Altogether, metabolic disorders including glucose/lipid metabolism, oxidative stress, mitochondrial dysfunction, and protein changes caused by DM are associated with an impaired insulin signal pathway. These metabolic factors could increase the prevalence of AD in diabetic patients via the promotion of A β pathology.

HIF-1α serves as a co-linker between AD and T2DM

Exploring the role of HIF-1α on pathogenesis in Alzheimer's disease and potential therapeutic approaches

Cross-Seeding Interaction Between Β-Amyloid and Human Islet Amyloid Polypeptide.

Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer's Disease: Beneficial or Detrimental?

Hyperinsulinemia-induced microglial mitochondrial dynamic and metabolic alterations lead to neuroinflammation in vivo and in vitro

HIF-1α Causes LCMT1/PP2A Deficiency and Mediates Tau Hyperphosphorylation and Cognitive Dysfunction during Chronic Hypoxia

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.

Deregulation of Brain Insulin Signaling in Alzheimer’s Disease

Humanin: a possible linkage between Alzheimer's disease and type 2 diabetes.

Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease

Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD

Association Between Type 2 Diabetes Mellitus and Alzheimer's Disease: Common Molecular Mechanism and Therapeutic Targets

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus

Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation.

Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway

Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions

Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease

An update on potential links between type 2 diabetes mellitus and Alzheimer’s disease

Amyloid-Beta Induces Hepatic Insulin Resistance By Activating Jak2/Stat3/Socs-1 Signaling Pathway

Hypoxia Facilitates Alzheimer's Disease Pathogenesis by Up-Regulating BACE1 Gene Expression

Metabolism: A Novel Shared Link Between Diabetes Mellitus and Alzheimer’s Disease